Where We Live Matters: Varied Disease Burden and Treatment Patterns in Psoriatic Arthritis in the United States
Arthritis & Rheumatology · 2026
DOI: 10.1002/art.43377 ↗Kurz gefasst
Fachartikel in der Zeitschrift Arthritis & Rheumatology, 2026. Verfasst von Brittany Banbury und 8 weiteren Autor:innen. Beteiligte Einrichtung: Icahn School of Medicine at Mount Sinai, New York, New York. Hauptthemen laut MEDLINE: Arthritis, Psoriatic, Antirheumatic Agents, Cost of Illness. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 50 Literaturangaben. Gefördert von: Janssen Scientific Affairs, NIAMS NIH HHS.
Abstract (Originalsprache)
Objective
To evaluate the clinical characteristics, social deprivation, insurance coverage, and medication use across regional subsets of patients with psoriatic arthritis (PsA) in the US.
Methods
A cross‐sectional study of patients with PsA in the Rheumatology Informatics System for Effectiveness (RISE) registry between January 2020 and March 2023 was conducted. Distribution of high disease activity (HDA; Routine Assessment of Patient Index Data >12), high comorbidity (RxRisk ≥90th percentile), high Area Deprivation Index (ADI ≥80), insurance coverage, prednisone ≥10 mg daily, and all disease‐modifying antirheumatic drug (DMARD) therapies across geographic regions were evaluated. Logistic regression models were used to identify regional correlates of HDA and comorbidity.
Results
Of the 32,732 RISE patients with PsA, 58.8% were White women (mean age 57.7 [SD 13.5] years) with private insurance (60%); 55.8% resided in the South. A majority (81.8%) had a body mass index of ≥25, highest in the Midwest (mean 32.4 ± SD 7.8). Women, despite having prevalent HDA, received less biologic DMARD therapy. Both HDA and ADI of ≥80 were more prevalent in the South and Midwest. Compared to the Northeast, Midwest patients had a higher burden of comorbidity (adjusted odds ratio 1.59, 95% confidence interval 0.98 – 2.59) with frequent use of prednisone in conjunction with conventional DMARDs (31.3% vs Northeast 20.5%, South 13.6%, West 17.6%). Uveitis affected 1.2% of the cohort. Only 14 (7.1%) and 20 (10.1%) RISE practices provided care for half of all Medicaid and high‐deprivation patients, respectively.
Conclusion
PsA disease characteristics and care vary across the US, with higher‐than‐expected prednisone use and unequal provider care burden in some regions. Further work is needed to assess the impact of varied regional care on disease outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Icahn School of Medicine at Mount Sinai, New York, New York.
- NEA Baptist Memorial Hospital, Jonesboro, Arkansas.
- Washington Veterans Affairs Medical Center, Washington, DC.
- Georgetown University, Washington, DC.
- Keck School of Medicine-Los Angeles General Medical Center, Los Angeles, California.
- University of Alabama at Birmingham.
ORCID-Profile: Brittany Banbury, Emily E Holladay
Förderung
- Janssen Scientific Affairs
- NIAMS NIH HHS
Zitieren
APA
Banbury, B., Dowell, S., Jenkins, C., Holladay, E. E., Xie, F., Zhang, J., Wright, G. C., Curtis, J. R., & Kerr, G. S. (2026). Where We Live Matters: Varied Disease Burden and Treatment Patterns in Psoriatic Arthritis in the United States. Arthritis & Rheumatology. https://doi.org/10.1002/art.43377
Vancouver
Banbury B, Dowell S, Jenkins C, Holladay EE, Xie F, Zhang J, et al. Where We Live Matters: Varied Disease Burden and Treatment Patterns in Psoriatic Arthritis in the United States. Arthritis & Rheumatology. 2026. doi:10.1002/art.43377
BibTeX
@article{Banbury2026,
author = {Banbury, Brittany and Dowell, Sharon and Jenkins, Christopher and Holladay, Emily E and Xie, Fenglong and Zhang, Jingyi and Wright, Grace C and Curtis, Jeffrey R and Kerr, Gail S},
title = {Where We Live Matters: Varied Disease Burden and Treatment Patterns in Psoriatic Arthritis in the United States},
journal = {Arthritis & Rheumatology},
year = {2026},
doi = {10.1002/art.43377}
}
EUVIMED